Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALZNNASDAQ:GDTCNASDAQ:RAINNASDAQ:RVLP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$3.04+0.7%$4.58$2.90▼$135.54$2.43M-0.27458,300 shs168,566 shsGDTCCytoMed Therapeutics$2.25-3.5%$2.27$1.20▼$4.05N/A-0.3378,548 shs1,420 shsRAINRain Enhancement Technologies Holdco$2.88-5.6%$1.21$0.82▼$11.32$21.85M-0.2112,309 shs14,098 shsRVLPRVL Pharmaceuticals$0.04$0.03▼$1.91N/AN/AN/A63.96 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro0.00%-6.17%-16.71%-66.88%-91.96%GDTCCytoMed Therapeutics0.00%+5.98%+2.00%-14.81%+13.59%RAINRain Enhancement Technologies Holdco0.00%-17.24%-31.75%+34.58%+138.02%RVLPRVL Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALZNAlzamend Neuro2.3722 of 5 stars3.52.00.00.01.14.20.0GDTCCytoMed Therapeutics2.2129 of 5 stars3.55.00.00.00.00.00.0RAINRain Enhancement Technologies HoldcoN/AN/AN/AN/AN/AN/AN/AN/ARVLPRVL PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALZNAlzamend Neuro 3.00Buy$180.005,821.05% UpsideGDTCCytoMed Therapeutics 3.00Buy$5.00122.32% UpsideRAINRain Enhancement Technologies Holdco 0.00N/AN/AN/ARVLPRVL Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALZNAlzamend NeuroN/AN/AN/AN/A($31.66) per shareN/AGDTCCytoMed Therapeutics$50KN/AN/AN/A$0.61 per shareN/ARAINRain Enhancement Technologies HoldcoN/AN/AN/AN/A($0.96) per shareN/ARVLPRVL Pharmaceuticals$49.72M0.00N/AN/AN/ANaNCompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALZNAlzamend Neuro-$9.95MN/A0.00N/AN/AN/A-497.73%-147.21%7/29/2025 (Estimated)GDTCCytoMed Therapeutics-$1.84MN/A0.00∞N/AN/AN/AN/A7/28/2025 (Estimated)RAINRain Enhancement Technologies Holdco-$4.53MN/A0.00∞N/AN/AN/A-43.86%N/ARVLPRVL Pharmaceuticals-$51.69MN/A0.00N/AN/AN/AN/AN/AN/ALatest RVLP, RAIN, GDTC, and ALZN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025RAINRain Enhancement Technologies HoldcoN/A-$0.20N/A-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALZNAlzamend NeuroN/AN/AN/AN/AN/AGDTCCytoMed TherapeuticsN/AN/AN/AN/AN/ARAINRain Enhancement Technologies HoldcoN/AN/AN/AN/AN/ARVLPRVL PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALZNAlzamend NeuroN/A5.445.44GDTCCytoMed Therapeutics0.059.899.89RAINRain Enhancement Technologies HoldcoN/A0.090.09RVLPRVL PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALZNAlzamend Neuro49.61%GDTCCytoMed Therapeutics0.04%RAINRain Enhancement Technologies Holdco25.79%RVLPRVL Pharmaceuticals14.36%Insider OwnershipCompanyInsider OwnershipALZNAlzamend Neuro30.21%GDTCCytoMed TherapeuticsN/ARAINRain Enhancement Technologies Holdco47.70%RVLPRVL Pharmaceuticals4.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALZNAlzamend Neuro4800,000559,000No DataGDTCCytoMed TherapeuticsN/AN/AN/ANot OptionableRAINRain Enhancement Technologies Holdco637.59 million3.97 millionNo DataRVLPRVL Pharmaceuticals125111.41 million106.50 millionOptionableRVLP, RAIN, GDTC, and ALZN HeadlinesRecent News About These CompaniesUnravel Biosciences Receives FDA Orphan Drug Designation for Vorinostat (RVL-001) as a Treatment for Rett SyndromeMay 28, 2024 | tmcnet.comRaval ICS Ltd.May 17, 2024 | wsj.comRVLPQ RVL Pharmaceuticals plcMarch 2, 2024 | seekingalpha.comRVL Pharmaceuticals PLC RVLPQJanuary 11, 2024 | morningstar.comRVL Pharmaceuticals plc’s latest rating changes from various analystsOctober 18, 2023 | knoxdaily.comRVL Pharmaceuticals Shares Plummet 50% as Subsidiaries File For BankruptcyOctober 13, 2023 | marketwatch.comSpecialty Pharma Firm RVL Pharmaceuticals Subsidiaries File for BankruptcyOctober 12, 2023 | benzinga.comRVL Subsidiaries To Effectuate Change Of Control; RVLP Ordinary Shares Expected To Be CancelledOctober 12, 2023 | markets.businessinsider.comRVL Pharmaceuticals Subsidiaries File for BankruptcyOctober 12, 2023 | finance.yahoo.comRVL Pharmaceuticals plc [RVLP] Investment Guide: What You Need to KnowOctober 11, 2023 | knoxdaily.comWhy Is RVL Pharmaceuticals (RVLP) Stock Up 28% Today?October 6, 2023 | investorplace.comInvesting in RVL Pharmaceuticals plc [RVLP]: What You Must KnowOctober 4, 2023 | knoxdaily.comUnderstanding the Risks of Investing in RVL Pharmaceuticals plc (RVLP)September 27, 2023 | knoxdaily.comRVLP Shares Experience Surge in ValueSeptember 21, 2023 | knoxdaily.comExamining the Potential Price Growth of RVL Pharmaceuticals plc (RVLP)September 13, 2023 | knoxdaily.comAnalysts predict RVLP shares will perform strongly in 2023September 7, 2023 | knoxdaily.comRVL Pharmaceuticals plc [RVLP] Investment Appeal on the RiseAugust 23, 2023 | knoxdaily.comUnmasking the Value Trap: A Deep Dive into RVL Pharmaceuticals PLCAugust 23, 2023 | finance.yahoo.comRVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 23, 2023 | finance.yahoo.comRVL Pharmaceuticals (RVLP) Gets a Buy from H.C. WainwrightAugust 21, 2023 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRVLP, RAIN, GDTC, and ALZN Company DescriptionsAlzamend Neuro NASDAQ:ALZN$3.04 +0.02 (+0.66%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.05 +0.01 (+0.33%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.CytoMed Therapeutics NASDAQ:GDTC$2.25 -0.08 (-3.48%) Closing price 06/20/2025 03:50 PM EasternExtended Trading$2.20 -0.04 (-1.96%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.Rain Enhancement Technologies Holdco NASDAQ:RAINAs of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.RVL Pharmaceuticals NASDAQ:RVLPRVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
